electroCore Stock Price

-0.04 (-2.26%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
electroCore Inc ECOR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -2.26% 1.73 19:40:29
Close Price Low Price High Price Open Price Previous Close
1.67 1.65 1.78 1.66 1.77
Bid Price Ask Price Spread News
1.67 1.73 0.06 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,307 336,619 $ 1.69 $ 570,412 1,199,915 0.3201 - 5.02
Last Trade Time Type Quantity Stock Price Currency
19:08:59 formt 100 $ 1.73 USD

electroCore Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 77.03M 44.53M 35.61M $ 2.39M $ - -1.53 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 6.70%

more financials information »

electroCore News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ECOR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.451.941.411.71682,6520.2819.31%
1 Month1.8932.071.301.71800,615-0.163-8.61%
3 Months0.8254.250.781.885,447,4710.905109.7%
6 Months0.51454.250.391.633,461,5391.22236.25%
1 Year5.025.020.32011.631,863,590-3.29-65.54%
3 Years18.0020.250.32012.06920,136-16.27-90.39%
5 Years18.0020.250.32012.06920,136-16.27-90.39%

electroCore Description

electroCore, Inc. is a medical device company, engaged in the commercialization and development of a platform non-invasive Vagus Nerve Stimulation ("nVNS") therapy that can be self-administered by patients. electroCore was founded in 2005 and has primarily focused on headache conditions (migraine and cluster headache). In July 2020, the U.S. Food and Drug Administration ("FDA") granted the Company an Emergency Use Authorization (EUA) authorizing the use of the Company's gammaCore Sapphire(TM) CV nVNS therapy at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.